Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Can wine consumption affect lipitor's cholesterol lowering ability?
Mebendazole for kids price?
Guselkumab brand name?
Motegrity ingredients?
Patent tenofovir alafenamide gilead?

Soliqua 100/33 initiation?

Soliqua 100/33 Initiation Guide

Soliqua (glargine 100 U/mL + aspart 33 U/mL) is a ready‑to‑inject pre‑filled pen that delivers a basal (glargine) and a rapid‑acting prandial (aspart) dose in a single cartridge. The 100/33 ratio means that 1 mL of the solution contains 100 U of glargine and 33 U of aspart.

Indication – Primarily used for patients with type 2 diabetes mellitus (T2DM) who are not achieving glycemic targets on oral agents or basal insulin alone. It is not approved for type 1 diabetes.

Below is a practical, step‑by‑step approach to initiating Soliqua 100/33. Adaptations may be required based on local formulary, patient factors, and your clinical judgement.

1. Pre‑Initiation Assessment

Item Why It Matters Typical Action
HbA1c & Fasting Glucose Determines starting dose Use HbA1c to estimate baseline insulin needs.
Body weight & BMI Guides basal dose (U/kg)
Renal & hepatic function Impacts insulin clearance Dose adjustments may be needed for CKD (≥ stage 3) or severe hepatic disease.
History of hypoglycemia Safety Exclude patients with a history of severe hypoglycemia without appropriate education.
Concomitant meds Interactions, sulfonylurea/repaglinide risk If on sulfonylureas, consider stepping down before insulin to avoid additive hypoglycemia risk.
Diabetes education level Ensures comprehension of injection technique Provide written instructions and hands‑on demonstration.
Availability of SMBG or CGM Essential for titration If CGM is not available, rely on finger‑stick SMBG at least twice daily.

2. Basal (Glargine) Component

Step Recommendation Rationale
Starting basal dose 0.2–0.3 U/kg or 10 U (whichever is higher) at bedtime Most patients with T2DM start in this range. 0.2–0.3 U/kg provides a moderate basal coverage.
First dose adjustment Increase by 2 U every 3–4 days if fasting glucose > 130 mg/dL (7.2 mmol/L) Small increments minimize hypoglycemia.
Target fasting glucose 80–130 mg/dL (4.4–7.2 mmol/L) Aligns with ADA/EASD targets for most adults.
Maximum basal dose ≤ 40 U/day Practical ceiling; higher doses rarely needed.
Storage Store in refrigerator (2–8 °C) until first use. After first use, keep at room temperature (≤ 30 °C) for 28 days. Protects pen integrity.

3. Prandial (Aspart) Component

Step Recommendation Rationale
First prandial dose 0.5 U/kg before each main meal (breakfast, lunch, dinner). Typical starting point for prandial insulin.
Dose adjustment Increase by 1 U or 10 % of previous dose when post‑prandial glucose > 180 mg/dL (10 mmol/L) at the corresponding meal. Balanced titration to avoid both hyperglycemia and hypoglycemia.
Carb‑counting Provide simple carb‑to‑insulin ratio (e.g., 1 U per 15 g carbohydrate) if patient is ready. Empowers patients for self‑adjustment.
Target post‑meal glucose 90–180 mg/dL (5–10 mmol/L) Standard ADA target for most adults.
Maximum prandial dose Usually ≤ 0.8 U/kg per meal; may be higher if patient is very active or has high carb load. Avoid over‑correction.

4. Combined Pen Use

Each 3.5‑mL pen contains 350 U glargine and 115.5 U aspart.

  • Dose per injection: The pen allows you to select any dose up to 3.5 U (≈ 3.5 mL).
  • Example: If basal dose is 15 U (≈ 15 mL of glargine) and a prandial dose is 6 U (≈ 6 mL of aspart), you would set the pen to deliver 21 U in total. The pen will automatically calculate the proportion of each component.
  • Avoid exceeding the cartridge’s capacity: Do not combine basal and prandial doses that together exceed 3.5 U. If needed, use a separate pen for the basal dose.

5. Titration Schedule (First 4–6 Weeks)

  1. Week 1 – Basal 0.2 U/kg at bedtime; prandial 0.5 U/kg before each meal.
  2. Week 2–4 – Check fasting glucose each morning (before breakfast). If > 130 mg/dL, increase basal by 2 U.
  3. Week 2–4 – Check post‑meal glucose 2 h after meals. If > 180 mg/dL, increase prandial by 1 U or 10 %.
  4. Week 5–6 – Re‑evaluate HbA1c; adjust basal by 2 U if fasting < 80 mg/dL or > 130 mg/dL. Adjust prandial similarly.
  5. Beyond Week 6 – Continue fine‑tuning until fasting < 110 mg/dL and post‑meal < 140 mg/dL.

Use a simple titration log or a mobile app to keep track.

6. Patient Education Highlights

Topic Key Points
Injection technique • Rotate injection sites (abdomen, thigh, arm).
• Use a new needle each time.
• Inject at a 90° angle for subcutaneous, 45° if thinner.
Pen handling • Prime the pen before first use.
• Verify dose on the display.
• Do not touch the needle.
Hypoglycemia • Recognise symptoms (sweating, shakiness, confusion).
• Treat with 15 g fast‑acting carb; recheck in 15 min.<


Other Questions About Soliqua :

soliqua 100/33 diabetes medication Soliqua 100 33 for basal patients? Soliqua 100 33 mechanism of action? Generic soliqua? Soliqua 100 33 prescription? Soliqua 100/33 resources? Prescribing soliqua 100 33?